Canaccord Keeps Teva (TEVA) at Hold; Copaxone Expiration Remains Overhang
Canaccord Genuity its maintaining its Hold rating and $45 price target on Teva Pharmaceutical (NYSE: TEVA) following Q2 results issued ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)